These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 36896795)

  • 41. Accelerating Clinical Development of Idasanutlin through a Physiologically Based Pharmacokinetic Modeling Risk Assessment for CYP450 Isoenzyme-Related Drug-Drug Interactions.
    Umehara K; Cleary Y; Fowler S; Parrott N; Tuerck D
    Drug Metab Dispos; 2022 Mar; 50(3):214-223. PubMed ID: 34937801
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Creation of Novel Sensitive Probe Substrate and Moderate Inhibitor Models for a Comprehensive Prediction of CYP2C8 Interactions for Tucatinib.
    Templeton IE; Rowland-Yeo K; Jones HM; Endres CJ; Topletz-Erickson AR; Sun H; Lee AJ
    Clin Pharmacol Ther; 2024 Feb; 115(2):299-308. PubMed ID: 37971208
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin.
    Quinney SK; Zhang X; Lucksiri A; Gorski JC; Li L; Hall SD
    Drug Metab Dispos; 2010 Feb; 38(2):241-8. PubMed ID: 19884323
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis.
    Gupta N; Hanley MJ; Venkatakrishnan K; Bessudo A; Rasco DW; Sharma S; O'Neil BH; Wang B; Liu G; Ke A; Patel C; Rowland Yeo K; Xia C; Zhang X; Esseltine DL; Nemunaitis J
    J Clin Pharmacol; 2018 Feb; 58(2):180-192. PubMed ID: 28800141
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Application of Physiologically Based Pharmacokinetic Modeling in Understanding Bosutinib Drug-Drug Interactions: Importance of Intestinal P-Glycoprotein.
    Yamazaki S; Loi CM; Kimoto E; Costales C; Varma MV
    Drug Metab Dispos; 2018 Aug; 46(8):1200-1211. PubMed ID: 29739809
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Composite midazolam and 1'-OH midazolam population pharmacokinetic model for constitutive, inhibited and induced CYP3A activity.
    Wiebe ST; Meid AD; Mikus G
    J Pharmacokinet Pharmacodyn; 2020 Dec; 47(6):527-542. PubMed ID: 32772302
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes.
    Marzolini C; Rajoli R; Battegay M; Elzi L; Back D; Siccardi M
    Clin Pharmacokinet; 2017 Apr; 56(4):409-420. PubMed ID: 27599706
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Model-Based Drug-Drug Interaction Extrapolation Strategy From Adults to Children: Risdiplam in Pediatric Patients With Spinal Muscular Atrophy.
    Cleary Y; Gertz M; Grimsey P; Günther A; Heinig K; Ogungbenro K; Aarons L; Galetin A; Kletzl H
    Clin Pharmacol Ther; 2021 Dec; 110(6):1547-1557. PubMed ID: 34347881
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Physiologically Based Pharmacokinetic Model Predictions of Panobinostat (LBH589) as a Victim and Perpetrator of Drug-Drug Interactions.
    Einolf HJ; Lin W; Won CS; Wang L; Gu H; Chun DY; He H; Mangold JB
    Drug Metab Dispos; 2017 Dec; 45(12):1304-1316. PubMed ID: 28912253
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Quantification of the Time Course of CYP3A Inhibition, Activation, and Induction Using a Population Pharmacokinetic Model of Microdosed Midazolam Continuous Infusion.
    Nassar YM; Hohmann N; Michelet R; Gottwalt K; Meid AD; Burhenne J; Huisinga W; Haefeli WE; Mikus G; Kloft C
    Clin Pharmacokinet; 2022 Nov; 61(11):1595-1607. PubMed ID: 36195807
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil.
    Perdaems N; Blasco H; Vinson C; Chenel M; Whalley S; Cazade F; Bouzom F
    Clin Pharmacokinet; 2010 Apr; 49(4):239-58. PubMed ID: 20214408
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tipifarnib physiologically-based pharmacokinetic modeling to assess drug-drug interaction, organ impairment, and biopharmaceutics in healthy subjects and cancer patients.
    Okudaira N; Burt H; Mitra A
    CPT Pharmacometrics Syst Pharmacol; 2024 Aug; 13(8):1366-1379. PubMed ID: 38807307
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of drug-drug interactions for oncology therapies: in vitro-in vivo extrapolation model-based risk assessment.
    Waters NJ
    Br J Clin Pharmacol; 2015 Jun; 79(6):946-58. PubMed ID: 25443889
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Physiologically based pharmacokinetic modeling to predict the clinical effect of azole antifungal agents as CYP3A inhibitors on azelnidipine pharmacokinetics.
    Watanabe A; Kotsuma M
    Drug Metab Pharmacokinet; 2024 Apr; 55():101000. PubMed ID: 38458122
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prediction of Drug-Drug Interactions with Crizotinib as the CYP3A Substrate Using a Physiologically Based Pharmacokinetic Model.
    Yamazaki S; Johnson TR; Smith BJ
    Drug Metab Dispos; 2015 Oct; 43(10):1417-29. PubMed ID: 26180127
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Assessment of CYP3A-mediated drug interaction via cytokine (IL-6) elevation for mosunetuzumab using physiologically-based pharmacokinetic modeling.
    Chen Y; Ma F; Jones N; Deng R; Li C; Li CC
    CPT Pharmacometrics Syst Pharmacol; 2024 Feb; 13(2):234-246. PubMed ID: 38050329
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of Safety and Clinically Relevant Drug-Drug Interactions with Tucatinib in Healthy Volunteers.
    Topletz-Erickson A; Lee A; Rustia EL; Sun H; Mayor JG; Abdulrasool LI; Walker L; Endres CJ
    Clin Pharmacokinet; 2022 Oct; 61(10):1417-1426. PubMed ID: 35931943
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Physiologically Based Pharmacokinetic Model-Informed Drug Development for Polatuzumab Vedotin: Label for Drug-Drug Interactions Without Dedicated Clinical Trials.
    Samineni D; Ding H; Ma F; Shi R; Lu D; Miles D; Mao J; Li C; Jin J; Wright M; Girish S; Chen Y
    J Clin Pharmacol; 2020 Oct; 60 Suppl 1():S120-S131. PubMed ID: 33205435
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Physiologically based pharmacokinetic modelling to predict drug-drug interactions for encorafenib. Part I. Model building, validation, and prospective predictions with enzyme inhibitors, inducers, and transporter inhibitors.
    Kollipara S; Ahmed T; Praveen S
    Xenobiotica; 2023 May; 53(5):366-381. PubMed ID: 37609899
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Predicting the Effect of CYP3A Inducers on the Pharmacokinetics of Substrate Drugs Using Physiologically Based Pharmacokinetic (PBPK) Modeling: An Analysis of PBPK Submissions to the US FDA.
    Wagner C; Pan Y; Hsu V; Sinha V; Zhao P
    Clin Pharmacokinet; 2016 Apr; 55(4):475-83. PubMed ID: 26369776
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.